Citigroup’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-51,137
| Closed | -$459K | – | 7563 |
|
|
2016
Q3 | $459K | Buy |
51,137
+26,207
| +105% | +$186K | ﹤0.01% | 3968 |
|
|
2016
Q2 | $134K | Sell |
24,930
-53,825
| -68% | -$276K | ﹤0.01% | 4841 |
|
|
2016
Q1 | $363K | Buy |
78,755
+56,858
| +260% | +$229K | ﹤0.01% | 4495 |
|
|
2015
Q4 | $114K | Sell |
21,897
-62,336
| -74% | -$362K | ﹤0.01% | 5281 |
|
|
2015
Q3 | $509K | Buy |
84,233
+37,885
| +82% | +$464K | ﹤0.01% | 3724 |
|
|
2015
Q2 | $731K | Buy |
46,348
+10,058
| +28% | +$122K | ﹤0.01% | 3378 |
|
|
2015
Q1 | $395K | Buy |
36,290
+12,247
| +51% | +$125K | ﹤0.01% | 3960 |
|
|
2014
Q4 | $253K | Buy |
24,043
+21,844
| +993% | +$213K | ﹤0.01% | 4500 |
|
|
2014
Q3 | $21K | Sell |
2,199
-3,668
| -63% | -$37.5K | ﹤0.01% | 5906 |
|
|
2014
Q2 | $68K | Sell |
5,867
-44,826
| -88% | -$408K | ﹤0.01% | 4945 |
|
|
2014
Q1 | $507K | Buy |
50,693
+17,751
| +54% | +$256K | ﹤0.01% | 3452 |
|
|
2013
Q4 | $429K | Buy |
32,942
+21,436
| +186% | +$295K | ﹤0.01% | 3944 |
|
|
2013
Q3 | $172K | Buy |
11,506
+10,148
| +747% | +$122K | ﹤0.01% | 4284 |
|
|
2013
Q2 | $13K | Buy |
+1,358
| New | +$9.2K | ﹤0.01% | 6018 |
|
Citigroup's RPTP Position: Q4 2016 in Review
Citigroup sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 51,137 shares — an estimated $459K sold.
Citigroup first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $731K in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Citigroup reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Citigroup sold 51,137 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $459K.
- Citigroup first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Citigroup's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $731K in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.